AKRO - Akero Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
AKRO price evolution
AKRO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $310.36 | $623.85 | $234.21 | |
| Short term investments | $449.84 | $279.81 | $315.8 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $746.89 | $776.01 | $911.28 | $559.96 |
| Long term investments | $88.13 | $19.28 | ||
| Property, plant & equipment | $0.83 | $0.9 | $0.96 | $1.03 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $89.03 | $0.96 | $20.31 | |
| Total investments | $537.97 | $279.81 | $335.09 | |
| Total assets | $817.55 | $865.04 | $912.24 | $580.27 |
| Current liabilities | ||||
| Accounts payable | $25.22 | $14.57 | $13.78 | $7.04 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $43.29 | $31.17 | $30.26 | $19.13 |
| Long term debt | $35.12 | $35.64 | $35.55 | $25.78 |
| Total noncurrent liabilities | $35.8 | $35.73 | $25.84 | |
| Total debt | $35.64 | $35.55 | $25.78 | |
| Total liabilities | $79.22 | $66.98 | $65.99 | $44.97 |
| Shareholders' equity | ||||
| Retained earnings | -$756.13 | -$683.43 | -$627.44 | -$574.1 |
| Other shareholder equity | $2.1 | -$0.26 | -$0.08 | $0.27 |
| Total shareholder equity | $798.07 | $846.25 | $535.31 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $234.21 | $249.77 | $150.48 | $187.24 |
| Short term investments | $315.8 | $101.68 | $37.77 | $81.14 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $559.96 | $355.17 | $193.58 | $271.35 |
| Long term investments | $19.28 | |||
| Property, plant & equipment | $1.03 | $1.29 | $1.55 | $1.79 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $20.31 | $1.4 | $1.97 | $1.99 |
| Total investments | $335.09 | $101.68 | $37.77 | $81.14 |
| Total assets | $580.27 | $356.57 | $195.55 | $273.34 |
| Current liabilities | ||||
| Accounts payable | $7.04 | $7.97 | $6.71 | $3.43 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $19.13 | $19.08 | $25.13 | $13.11 |
| Long term debt | $25.78 | $9.54 | $1.31 | $1.52 |
| Total noncurrent liabilities | $25.84 | $10.93 | $1.31 | $1.52 |
| Total debt | $25.78 | $10.62 | $1.31 | $1.52 |
| Total liabilities | $44.97 | $30.01 | $26.44 | $14.63 |
| Shareholders' equity | ||||
| Retained earnings | -$574.1 | -$422.34 | -$310.3 | -$209.53 |
| Other shareholder equity | $0.27 | $0.04 | -$0.03 | -$0 |
| Total shareholder equity | $535.31 | $326.56 | $169.11 | $258.71 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $55.32 | $50.65 | $53.39 | |
| Selling, general & administrative | $10.42 | $9.3 | $8.48 | |
| Total operating expenses | $81.7 | $65.74 | $59.95 | $61.87 |
| Operating income | -$65.74 | -$59.95 | -$61.87 | |
| Income from continuing operations | ||||
| EBIT | -$54.76 | -$52.35 | -$54.29 | |
| Income tax expense | ||||
| Interest expense | $9 | $1.23 | $0.99 | $0.9 |
| Net income | ||||
| Net income | -$72.7 | -$55.99 | -$53.34 | -$55.19 |
| Income (for common shares) | -$55.99 | -$53.34 | -$55.19 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $141.8 | $85.28 | $81.76 | $64.92 |
| Selling, general & administrative | $31.07 | $29.87 | $19.13 | $15.24 |
| Total operating expenses | $172.87 | $115.16 | $100.89 | $80.15 |
| Operating income | -$172.87 | -$115.16 | -$100.89 | -$80.15 |
| Income from continuing operations | ||||
| EBIT | -$148.66 | -$111.29 | -$100.78 | -$79.21 |
| Income tax expense | ||||
| Interest expense | $3.1 | $0.74 | ||
| Net income | ||||
| Net income | -$151.76 | -$112.03 | -$100.78 | -$79.21 |
| Income (for common shares) | -$151.76 | -$112.03 | -$100.78 | -$79.21 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$55.99 | -$53.34 | -$55.19 | |
| Operating activities | ||||
| Depreciation | $0.06 | $0.06 | $0.06 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $7.66 | $7.4 | $6.12 | |
| Total cash flows from operations | -$57.45 | -$35.14 | -$48.63 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | -$254.9 | $57.85 | $12.79 | |
| Total cash flows from investing | -$124.98 | -$255.9 | $57.85 | $12.79 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.33 | $357.21 | $0.53 | |
| Net borrowings | $10 | |||
| Total cash flows from financing | $369.86 | -$0.15 | $366.94 | $0.5 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $81.86 | -$313.5 | $389.65 | -$35.34 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$151.76 | -$112.03 | -$100.78 | -$79.21 |
| Operating activities | ||||
| Depreciation | $0.26 | $0.26 | $0.24 | $0.21 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.5 | $23.24 | $10.05 | $6.02 |
| Total cash flows from operations | -$145.37 | -$92.52 | -$79.68 | -$70.8 |
| Investing activities | ||||
| Capital expenditures | -$0.15 | |||
| Investments | -$223.62 | -$63.83 | $42.28 | -$9.61 |
| Total cash flows from investing | -$223.62 | -$63.83 | $42.28 | -$9.76 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $339.09 | $246.28 | $1.12 | $203.06 |
| Net borrowings | $15 | $9.61 | ||
| Total cash flows from financing | $353.32 | $255.63 | $0.6 | $203.11 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$15.67 | $99.29 | -$36.8 | $122.54 |
News
Fundamentals
| Market cap | $2.56B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 69.61M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$237.22M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -10.78 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.41 |
|---|---|
| ROA | -29.89% |
| ROE | N/A |
| Debt/Equity | 0.08 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 17.25 |
| Quick ratio | N/A |